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                                                      INTRODUCTION 
 
                   It is universally accepted that Heart Failure is a complex clinical 
syndrome that can result from any structural or functional cardiac disorders 
that impairs the ability of ventricles to fill with or eject blood. Coronary artery 
disease accounts for a substantial portion of patients with chronic Heart 
failure. Heart failure is the end stage of all diseases of the heart and is a major 
cause of morbidity and mortality 1. 
                   Heart failure is a burgeoning problem worldwide. The prevalence of 
heart failure increases with age1. 
                   Heart failure is associated with elevations in circulating levels of 
Brain Natriuretic Peptide (BNP) and other markers like Uric acid, Troponin T 
and I, C- Reactive Protein, TNF Receptors, E- Selectin etc. 
         As Heart failure is a leading cause of mortality, the ability to predict 
prognosis is essential for optimal allocation of treatments. Biomarkers offering 
prognostic information are used in practice. Studies have shown that apart 
from Brain Natriuretic Peptide as a biomarker, Uric acid is found to have 
prognostic value as well2. 
       Increased Serum Uric acid in cardiovascular events may be a 
consequence of impairment of vascular Nitric Oxide, owing to the ability of 
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Nitric Oxide to modulate Uric acid through its influence on Xanthine Oxidase. 
Activation of Xanthine Oxidase through free radical release causes leucocyte 
and endothelial cell activation3. Increases in Uric acid are associated with 
increased vascular tone and depressed myocardial contractility via increase in 
Xanthine Oxidase activity. Thus Uric acid could be associated with 
haemodynamic compromise in heart failure. 
         Tamariz et al. in a metaanalysis in 2011 analyzed 1456 patients with 
Heart failure. Relative risk of all-cause mortality was found to be 2.13 for those 
with serum Uric acid > 6.5 mg/dl compared with uric acid < 6.5 mg/dl. A linear 
association was found between serum uric acid levels and mortality after 7 
mg/dl4. 
         Other Studies have shown that Uric acid is a strong independent 
marker of worser prognosis in patients with moderate to severe Congestive 
Heart Failure. In patients with heart failure, increased levels of serum Uric acid 
are highly predictive of mortality and are useful in identifying the need for 
Heart transplantation. 
          Hence Uric acid is valuable as a biomarker in patients with Heart 
Failure. 
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                                                   AIM OF THE STUDY 
 
• To evaluate serum uric acid levels in patients with heart failure. 
• To correlate serum uric acid levels with morbidity and mortality in 
patients  with heart failure. 
• To correlate serum uric acid levels with prognosis in heart failure. 
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REVIEW OF LITERATURE 
HISTORICAL REVIEW 
                    Descriptions of heart failure exist from ancient Egypt, Greece, and 
India. Little understanding of the nature of the condition can have existed until 
William Harvey described the circulation in 162853.                                                                           
                     Roentgen's discovery of X rays and Einthoven's development of 
electrocardiography in the 1890s led to improvements in the investigation of 
heart failure. The advent of echocardiography, cardiac catheterisation, and 
nuclear medicine have improved the investigation and diagnosis of patients 
with heart failure. 
                      It was not until the 20th century that diuretics were developed. 
The early, mercurial agents, however, were associated with substantial 
toxicity, unlike the thiazide diuretics, which were introduced in the 1950s. 
Vasodilators were not widely used until the development of angiotensin 
converting enzyme inhibitors in the 1970s. The landmark CONSENSUS-I study 
(first cooperative north Scandinavian enalapril survival study), published in 
1987, showed the unequivocal survival benefits of enalapril in patients with 
severe heart failure. 
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                     The therapy for heart failure has emerged from the use of diuretics 
and vasodilators to the use of implantable Cardioverter-Defibrillators, 
Ventricular Assist devices, LV reconstruction procedures, Cardiac 
resynchronisation therapy and Cardiac transplantation53. 
 
EPIDEMIOLOGY OF HEART FAILURE 
                    Heart failure is a burgeoning problem worldwide, with more than 
20 million people affected. The overall prevalence of HF in the adult population 
in developed countries is 2%1. 
                   Heart failure prevalence follows an exponential pattern, rising with 
age, and affects 6–10% of people over age 65. Although the relative incidence 
of HF is lower in women than in men, women constitute at least one-half of 
the cases of HF because of their longer life expectancy1. In North America and 
Europe, the lifetime risk of developing HF is approximately one in five for a 40-
year-old.  
                    The overall prevalence of HF is thought to be increasing, in part 
because current therapies for cardiac disorders, such as myocardial infarction 
(MI), valvular heart disease, and arrhythmias, are allowing patients to survive 
longer. Very little is known about the prevalence or risk of developing HF in 
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emerging nations because of the lack of population-based studies in these 
countries. 
                     Based on disease-specific estimates of prevalence and incidence 
rates of heart failure, it has been estimated that the prevalence of heart failure 
in India due to coronary heart disease, hypertension, obesity, diabetes and 
rheumatic heart disease ranges from 1.3 to 4.6 million, with an annual 
incidence of around 1.8 million54. 
                     Although HF once was thought to arise primarily in the setting of a 
depressed left ventricular (LV) ejection fraction (EF), epidemiologic studies 
have shown that approximately one-half of patients who develop HF have a 
normal or preserved EF (EF 40–50%). Accordingly, HF patients are now broadly 
categorized into one of two groups: (1) HF with a depressed EF (commonly 
referred to as systolic failure) or (2) HF with a preserved EF (commonly 
referred to as diastolic failure) 1. 
                      Any condition that leads to an alteration in LV structure or 
function can predispose a patient to developing HF. Although the etiology of 
HF in patients with a preserved EF differs from that of patients with depressed 
EF, there is considerable overlap between the etiologies of these two 
conditions. 
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                   In industrialized countries, coronary artery disease (CAD) has 
become the predominant cause in men and women and is responsible for 60–
75% of cases of HF. Hypertension contributes to the development of HF in 75% 
of patients, including most patients with CAD. Both CAD and hypertension 
interact to augment the risk of HF, as does diabetes mellitus. 
DEFINITION OF HEART FAILURE 
                     The most accepted and practical definition of heart failure 
appeared in 2001 ACC/AHA guidelines for the evaluation and management of  
heart failure in adults which states ‘’Heart Failure is a complex clinical 
syndrome that can result from any structural or functional cardiac disorders 
that impairs the ability of ventricles to fill with or eject blood’’53. 
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ETIOLOGY OF HEART FAILURE 
Depressed Ejection Fraction (<40%) 
Coronary artery disease Nonischemic dilated cardiomyopathy 
Myocardial infarction Familial/genetic disorders 
Myocardial ischemia Infiltrative disorders 
Chronic pressure overload Toxic/drug-induced damage 
Hypertension Metabolic disorder 
Obstructive valvular disease Viral 
Chronic volume overload Chagas' disease 
Regurgitant valvular disease Disorders of rate and rhythm 
Intracardiac (left-to-right) shunting Chronic bradyarrhythmias 
Extracardiac shunting Chronic tachyarrhythmias 
Preserved Ejection Fraction (>40–50%)  
Pathologic hypertrophy Restrictive cardiomyopathy 
Primary(hypertrophic  
cardiomyopathies) 
Infiltrative disorders (amyloidosis, 
sarcoidosis) 
Secondary (hypertension) Storage diseases (hemochromatosis) 
Aging Fibrosis 
 Endomyocardial disorders 
Pulmonary Heart Disease  
Cor pulmonale  
Pulmonary vascular disorders  
High-Output States  
Metabolic disorders Excessive blood-flow requirements 
Thyrotoxicosis Systemic arteriovenous shunting 
Nutritional disorders (beriberi) Chronic anemia 
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                          In 20–30% of the cases of HF with a depressed EF, the exact 
etiologic basis is not known. These patients are referred to as having 
nonischemic, dilated, or idiopathic cardiomyopathy if the cause is unknown. 
Prior viral infection or toxin exposure (e.g., alcoholic or chemotherapeutic) also 
may lead to a dilated cardiomyopathy1. 
                           Moreover, it is becoming increasingly clear that a large number 
of cases of dilated cardiomyopathy are secondary to specific genetic defects, 
most notably those in the cytoskeleton. Most forms of familial dilated 
cardiomyopathy are inherited in an autosomal dominant fashion. Mutations of 
genes that encode cytoskeletal proteins (desmin, cardiac myosin, vinculin) and 
nuclear membrane proteins (laminin) have been identified thus far. 
                          Dilated cardiomyopathy also is associated with Duchenne's, 
Becker's, and limb-girdle muscular dystrophies. Conditions that lead to a high 
cardiac output (e.g., arteriovenous fistula, anemia) are seldom responsible for 
the development of HF in a normal heart; however, in the presence of 
underlying structural heart disease, these conditions can lead to overt HF1. 
PATHOGENESIS OF HEART FAILURE 
                          Heart failure syndrome always begins with an index event. The 
index or the initiating event may be clinically silent, such as the expression of a 
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genetic mutation, or obvious, such as the catastrophic, sudden loss of a large 
mass of contractile tissue from acute myocardial infarction.  
                          The index event could be the explosive onset of fulminant viral 
myocarditis, or it may be prolonged and insidious, such as that occurs with 
valvular heart disease. The phenotypic expression of left ventricle dilation and 
impaired systolic function can also be slow to develop, such as a pressure or 
volume overloaded  state from valvular or coronary heart disease. The clinical 
picture can also be more rapidly progressive, as sometimes occurs with familial 
cardiomyopathy. 
                          In most instances, patients remain asymptomatic or minimally 
symptomatic after the initial decline in pumping capacity of the heart or 
develop symptoms only after the dysfunction has been present for some time.  
                         The list of compensatory mechanisms that have been described 
thus far include (1) activation of the renin-angiotensin-aldosterone (RAA) and 
adrenergic nervous systems, which are responsible for maintaining cardiac 
output through increased retention of salt and water, and (2) increased 
myocardial contractility. In addition, there is activation of a family of 
countervailing vasodilatory molecules, including the atrial and brain natriuretic 
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peptides (ANP and BNP), prostaglandins (PGE2 and PGI2), and nitric oxide 
(NO), that offsets the excessive peripheral vascular vasoconstriction. 
                            Although the exact mechanisms that are responsible for this 
transition are not known, the transition to symptomatic HF is accompanied by 
increasing activation of neurohormonal, adrenergic, and cytokine systems that 
lead to a series of adaptive changes within the myocardium collectively 
referred to as LV remodelling. 
 
STAGES OF HEART FAILURE 
 
Stage A: Patients at high risk for developing HF in the future but no functional 
or structural heart disorder; 
Stage B: A structural heart disorder but no symptoms at any stage; 
Stage C: Previous or current symptoms of heart failure in the context of an 
underlying structural heart problem, but managed with medical treatment; 
Stage D: Refractory and advanced disease requiring hospital-based support, a 
heart transplant or palliative care. 
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NYHA CLASSIFICATION OF HEART FAILURE
75 
Class I (Mild) 
No limitation of physical activity. Ordinary physical activity does not cause 
undue fatigue, palpitation, or dyspnea (shortness of breath). 
Class II (Mild) 
Slight limitation of physical activity. Comfortable at rest, but ordinary physical 
activity results in fatigue, palpitation, or dyspnea. 
Class III (Moderate) 
Marked limitation of physical activity. Comfortable at rest, but less than 
ordinary activity causes fatigue, palpitation, or dyspnea. 
Class IV (Severe) 
Unable to carry out any physical activity without discomfort. Symptoms of 
cardiac insufficiency at rest. If any physical activity is undertaken, discomfort is 
increased. 
Other systems like the ESC guidelines can also be used for staging of heart 
failure.55 
MECHANISMS OF HEART FAILURE 
Systolic dysfunction 
                 LV remodeling develops in response to a series of complex events 
that occur at the cellular and molecular levels. These changes include (1) 
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myocyte hypertrophy, (2) alterations in the contractile properties of the 
myocyte, (3) progressive loss of myocytes through necrosis, apoptosis, and 
autophagic cell death, (4) -adrenergic desensitization, (5) abnormal myocardial 
energetics and metabolism, and (6) reorganization of the extracellular matrix 
with dissolution of the organized structural collagen weave surrounding 
myocytes and subsequent replacement by an interstitial collagen matrix that 
does not provide structural support to the myocytes. The biologic stimuli for 
these profound changes include mechanical stretch of the myocyte, circulating 
neurohormones (e.g., norepinephrine, angiotensin II), inflammatory cytokines 
[e.g., tumor necrosis factor (TNF)], other peptides and growth factors (e.g., 
endothelin), and reactive oxygen species (e.g., superoxide). The sustained 
overexpression of these biologically active molecules is believed to contribute 
to the progression of HF by virtue of the deleterious effects they exert on the 
heart and the circulation. Indeed, this insight forms the clinical rationale for 
using pharmacologic agents that antagonize these systems [e.g., angiotensin-
converting enzyme (ACE) inhibitors and beta blockers] for treating  HF. 
Diastolic dysfunction 
                Myocardial relaxation is an adenosine triphosphate (ATP)-dependent 
process that is regulated by uptake of cytoplasmic calcium into the SR by 
SERCA2A and extrusion of calcium by sarcolemmal pumps. Accordingly, 
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reductions in ATP concentration, as occurs in ischemia, may interfere with 
these processes and lead to slowed myocardial relaxation. Alternatively, if LV 
filling is delayed because LV compliance is reduced (e.g., from hypertrophy or 
fibrosis), LV filling pressures will similarly remain elevated at end diastole. An 
increase in heart rate disproportionately shortens the time for diastolic filling, 
which may lead to elevated LV filling pressures, particularly in noncompliant 
ventricles. Elevated LV end-diastolic filling pressures result in increases in 
pulmonary capillary pressures, which can contribute to the dyspnea 
experienced by patients with diastolic dysfunction. In addition to impaired 
myocardial relaxation, increased myocardial stiffness secondary to cardiac 
hypertrophy and increased myocardial collagen content may contribute to 
diastolic failure. Importantly, diastolic dysfunction can occur alone or in 
combination with systolic dysfunction in patients with HF. 
DIAGNOSIS 
                     No system of diagnostic criteria has been agreed as the gold 
standard for heart failure. Commonly used systems are the "Framingham 
criteria" (derived from the Framingham Heart Study), the "Boston criteria"57, 
the "Duke criteria58", and (in the setting of acute myocardial infarction) the 
"Killip class"59. 
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Framingham criteria  
 
                    By the Framingham criteria, diagnosis of congestive heart failure 
(heart failure with impaired pumping capability) requires the simultaneous 
presence of at least 2 of the following major criteria or 1 major criterion in 
conjunction with 2 of the following minor criteria: 
Major criteria56:  
 
 Cardiomegaly on chest radiography  
 S3 gallop (a third heart sound)  
 Acute pulmonary edema  
 Paroxysmal nocturnal dyspnea  
 Crackles on lung auscultation  
 Central venous pressure of more than 16 cm H2O at the right atrium  
 Jugular vein distension  
 
  Positive abdominojugular test 
 
 Weight loss of more than 4.5 kg in 5 days in response to treatment 
(sometimes classified as a minor criteria)  
 
Minor criteria56:  
 
  Tachycardia of more than 120 beats per minute  
 
  Nocturnal cough  
16 
 
  Dyspnea on ordinary exertion  
  Pleural effusion  
  Decrease in vital capacity by one third from maximum recorded  
  Hepatomegaly  
 Bilateral ankle edema  
 
 
Minor criteria are acceptable only if they cannot be attributed to another 
medical condition such as pulmonary hypertension, chronic lung disease, 
cirrhosis, ascites, or the nephrotic syndrome. The Framingham Heart Study 
criteria are 100% sensitive and 78% specific for identifying persons with 
definite congestive heart failure. 
 
Imaging 
               Echocardiography is commonly used to support a clinical diagnosis of 
heart failure. This modality uses ultrasound to determine the stroke volume 
(SV, the amount of blood in the heart that exits the ventricles with each beat), 
the end-diastolic volume (EDV, the total amount of blood at the end of 
diastole), and the SV in proportion to the EDV, a value known as the ejection 
fraction (EF).  
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                         In pediatrics, the shortening fraction is the preferred measure of      
systolic function. Normally, the EF should be between 50% and 70%; in systolic 
heart failure, it drops below 45%. Echocardiography can also identify valvular 
heart disease and assess the state of the pericardium (the connective tissue 
sac surrounding the heart). Echocardiography may also aid in deciding what 
treatments will help the patient, such as medication, insertion of an 
implantable cardioverter-defibrillator or cardiac resynchronization therapy. 
                        Echocardiography can also help determine if acute myocardial 
ischemia is the precipitating cause, and may manifest as regional wall motion 
abnormalities on echo.  
                        Chest X-rays are frequently used to aid in the diagnosis of CHF. In 
the compensated patient, this may show cardiomegaly (visible enlargement of 
the heart), quantified as the cardiothoracic ratio (proportion of the heart size 
to the chest). In left ventricular failure, there may be evidence of vascular 
redistribution ("upper lobe blood diversion" or "cephalization"), Kerley lines, 
cuffing of the areas around the bronchi, and interstitial edema. 
RISK STRATIFICATION IN CHRONIC HEART FAILURE
60
 
                       Risk stratification is prudent to determine the mortality and 
morbidity profile of patients with HF. It helps to identify patients who are at 
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low risk and therefore can be managed medically. Invasive procedures should 
be reserved for patients at high risk of mortality.  
                        The following parameters are strongly associated with increased 
mortality in chronic heart failure and are recommended in risk stratification.  
• Advanced age  
• Low serum sodium  
• VO2 max (mL/kg per min <10–14)  
• Low LV ejection fraction61  
• Resuscitated sudden arrest  
• NYHA functional Class III–IV  
• Persistent low BP  
• High serum BNP62,71 
• Increased left ventricular volumes  
• High serum creatinine  
• High serum bilirubin  
              Studies show that low body-mass index, broad QRS63, T-wave 
alternans64, low heart rate variability, low 6 min walking ability, high left 
ventricular filling pressure, restrictive mitral filling pattern65, impaired right 
ventricular function, high serum uric acid66, high plasma interleukin –667, high 
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plasma oxidised LDL68, low cardiac index, high resting heart rate and high 
serum norepinephrine69 portend a bad prognosis in these patients. Recently 
homocysteine70 levels are found to be associated with increased risk of heart 
failure. The inherent limitations associated with these factors necessitate the 
use of more than one factor in prognostication of chronic HF. Predictability and 
cost efficacy concerns have inculcated further studies in this area. 
BIOMARKERS 
              While the diagnosis of heart failure remains based on a clinical 
presentation of breathlessness, fluid overload, and haemodynamic 
derangement, heart failure is really comprised of varied underlying 
pathophysiologies that carry a range of prognoses and may require a range of 
treatment strategies. Multi-modal imaging of the heart allows refinement of 
diagnosis and prognosis, yet still views cardiac failure from a macroscopic 
perspective. The field of ‘biomarker medicine' has therefore risen in attempt to 
further hone our ability to classify and perhaps treat heart failure at a 
molecular level72.  
               To date, numerous measurable serum molecules have been 
characterized in the context of heart failure, and these may be broadly 
classified as markers of inflammation, oxidative stress, extracellular 
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remodelling, neurohormonal activation, myocyte injury, and myocyte stress. 
Biomarkers should be expected to vary in relation to the underlying 
pathophysiology, with some being only markers of advanced heart failure, and 
others possibly playing a true pathophysiological role in disease progression72. 
                 Circulating levels of natriuretic peptides are useful adjunctive tools in 
the diagnosis of patients with HF. Both B-type natriuretic peptide (BNP) and N-
terminal pro-BNP, which are released from the failing heart, are relatively 
sensitive markers for the presence of HF with depressed EF; they also are 
elevated in HF patients with a preserved EF, albeit to a lesser degree. However, 
it is important to recognize that natriuretic peptide levels increase with age 
and renal impairment, are more elevated in women, and can be elevated in 
right HF from any cause. Levels can be falsely low in obese patients and may 
normalize in some patients after appropriate treatment. At present, serial 
measurements of BNP are not recommended as a guide to HF therapy1. Other 
biomarkers, such as troponin T and I, C-reactive protein, TNF receptors, and 
uric acid, may be elevated in HF and provide important prognostic 
information1. Serial measurements of one or more biomarkers ultimately may 
help guide therapy in HF, though not currently recommended for this purpose. 
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URIC ACID PHYSIOLOGY AND PURINE METABOLISM IN HUMANS  
                  Uric acid is the final breakdown product of dietary or endogenous 
purines and is generated by xanthine dehydrogenase (xanthine oxidase) 
primarily in the liver and intestine. Exogenous purines also represent an 
important source of uric acid, and approximately 50% of RNA purines and 25% 
of DNA purines are absorbed in the intestine and subsequently excreted in 
urine73. 
                   In adult humans, the uric acid pool is around 1.2g and undergoes 
rapid turnover, with two thirds of the uric acid pool excreted in urine. The 
kidneys handle urates in multiple processes, including glomerular filtration and 
reabsorption, secretion, and post secretory absorption in the proximal   
convoluted    tubules73. The urate handling by kidneys could be affected by 
various factors like extra cellular volume status, urine flow rate, urine pH, urate 
load, and hormones73. 
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                In addition, several pharmacologic agents (prebenecid, salicylates, 
antihypertensives like angiotensin II  antagonists)  also influence urate 
excretion. Serum uric acid is also modulated by exercise, diet. However, 
persistent hyperuricemia typically occurs due to defective renal clearance. The 
limited solubility of uric acid and the absence of enzyme uricase lead to a 
number of clinical conditions including gout and uric acid kidney stones73. 
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 POTENTIAL MECHANISMS FOR INCREASED URIC ACID IN HEART FAILURE 
                   UA is a metabolic byproduct of purine metabolism. Serum UA may 
increase in the failing circulation because of increased generation, decreased 
excretion, or a combination of the 2 factors. There are several possible 
contributors to increased UA production in HF, including increased abundance 
and activity of XO, increased conversion of xanthine dehydrogenase (XDH) to 
XO, or increased XO substrate resulting from enhanced ATP breakdown to 
adenosine and hypoxanthine. As UA is excreted primarily by the kidney, 
decreased renal perfusion could lead to increased UA levels. To the extent that 
HF leads to tissue ischemia (in advanced HF) and a rise in serum lactate, renal 
UA excretion can be further impaired as lactate competes with urate via an 
organic anion exchanger in the proximal tubule. 
URIC ACID  AND  XANTHINE  OXIDASE  IN  HEART FAILURE 
PATHOPHYSIOLOGY 
 
                      The role of UA as an independent risk factor for the progression of 
HF remains unclear. To date, a clear pathophysiological link between 
hyperuricemia and cardiovascular complications has yet to be confirmed and 
UA has been related to many of the established risk factors for HF, including 
dyslipidemia and hypertension48, implying that UA may instead be a marker of 
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increased risk. Several population studies have evaluated whether UA is an 
independent and causal risk factor but the evidence remains inconsistent and 
controversial48. 
 
 
 
                    Serum uric acid (SUA) is a byproduct of purine catabolism, the 
terminal steps of which are catalyzed by xanthine oxidoreductase (XOR)74 . 
Serum UA may increase in the failing circulation because of increased 
generation, decreased excretion, or a combination of the 2 factors.  
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                      The source of uric acid in the failing heart seems supported by the 
fact that SUA level has been found to be elevated in the coronary sinus in HF4 
when compared with control patients.  
                     Beyond XO activity, recent experimental studies suggest that UA 
itself may have a role in cardiovascular and renal pathophysiology. This might 
seem surprising, as UA can function as an antioxidant, both by itself and by 
promoting superoxide dismutase activity, 3 and might therefore be considered 
potentially protective. However, UA potently stimulates vascular smooth 
muscle cell proliferation in vitro, an effect mediated by stimulation of mitogen-
activated protein kinases, cyclooxygenase-2, and platelet-derived growth 
factor. Furthermore, rats with mild experimentally induced hyperuricemia 
develop intrarenal vascular disease with increased renin expression, systemic 
and glomerular hypertension, and renal injury in the absence of intrarenal 
crystal deposition16,15. 
                     Data from several experimental animal studies indicate that 
hyperuricemia is associated with the down-regulation of nitric oxide (NO) in 
endothelial smooth muscle through an increase in reactive oxygen species 
(ROS)6. ROS reduces the bioavailability of endothelial NO and leads to 
endothelial dysfunction through a loss in NO-dependent vasodilation.6 
Meanwhile, UA is a potent antioxidant that might counteract the effect of ROS, 
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but there is evidence that hyperuricemia by itself reduces the abundance of 
NO-synthase and impairs NO-mediated vasodilation.24 
                      Accumulating data also suggest that UA, aside from being a 
potentially valuable prognostic marker, possesses certain toxic or other effects 
that may contribute to HF pathophysiology beyond a reflection of increased XO 
activity. Experimental studies in animals have reported that UA is a potent 
stimulator of intrarenal vascular smooth muscle cell proliferation,26 an effect 
that may lead to significant hemodynamic changes in the failing circulation. 
                       Human atherosclerotic plaque has been shown to contain a 
considerable amount of uric acid, and hyperuricemia may promote thrombus 
formation via purine metabolism20. In addition, increased uric acid 
concentrations are associated with the increased production of oxygen free 
radicals, promote oxygenation of LDL cholesterol, and facilitate lipid 
peroxidation 20. Each of these factors is known to play a crucial role in the 
progression of atherosclerosis. 
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FACTORS THAT AFFECT URATE LEVEL  
Dietary Habits  
An increase in serum urate level may occur in purine rich diet such as Non-
vegetarian diets – liver, anchovies, kidneys, sardines and sweet breads and 
yeasts.  
Exercise  
Exercise acutely increases serum urate levels by excessive degradation of 
skeletal ATP.  
Alcohol  
Alcohol increases serum urate level by accumulation of organic acids (beta 
hydroxyl butyrate, aceto-acetate, lactate) that compete with the urate for 
tubular secretion and accelerated breakdown of ATP by liver is increased. (Beer 
contains high uric acid)  
Obesity  
Various mechanisms play role in increase of serum urate by obesity, like 
anabolic effects of tissues because of insulin resistance, increase in de novo 
biosynthesis of purines, decreased excretion and increased breakdown.  
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Dehydration  
Dehydration can impair uric acid excretion by decreased filtration and 
secretion and sometimes with the acidosis by competition of H+ ions for 
excretion. Starvation again causes accumulation of organic acids that compete 
for the excretion of urate for tubular secretion.  
Systemic Hypertension  
There are various studies regarding association of systemic hypertension with 
the elevated uric acid levels. Probable mechanism suggested is impaired 
excretion of urate because of intrinsic renal defect in HT.  
Hyperglycemia  
Both uric acid and glucose levels are positively related to body mass index. The 
association of uric acid in relation to glucose reflects the biochemical 
interaction between serum glucose and purine metabolism. (Deranged 
carbohydrate metabolism)  
Renal Insufficiency  
Decreased urate filtration contributes to the hyperuricemia of renal 
insufficiency. But the correlation between BUN, serum creatinine and serum 
uric acid concentration is poor because although uric acid excretion per unit of 
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GFR increases progressively with renal insufficiency, the tubular secretory 
capacity tends to be preserved, the tubular reabsorptive capacity is decreased 
and extrarenal clearance of uric acid increases as the renal damage becomes 
more severe. 
Drugs 
They mainly act by decreasing the uric acid excretion by competitive inhibition 
of uric acid excretion. Salicylates and nicotinic acid directly compete with the 
urate for tubular secretion. Diuretics decrease the secretory capacity and 
increase reabsorption. L-Dopa, pyrazinamide, ethambutol, cyclosporine also 
decrease the secretion of urate by the tubules.  
URIC ACID IN CARDIOVASCULAR DISEASE 
                      Uric acid has often been considered a part of the dysmetabolic 
syndrome or simply a marker of other coronary disease risk factors such as 
hypertension, dyslipidemia, glucose intolerance and renal diseases.  
                      However, most epidemiological studies have demonstrated a 
significant association between serum uric acid and CV morbidity and 
mortality. Serum   levels are associated with the occurrence of stroke and MI 
(myocardial infarction) as well as all CV-related events. The link has been 
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studied in the general population as well as in persons with diabetes mellitus, 
congestive heart diseases, angiographically confirmed coronary artery  
diseases (CAD) and hypertension50. Hyperuricemia is frequently encountered in 
hypertensive patients  and  may occur due to a defect in renal urate clearance. 
Patients with hypertension and hyperuricemia have a 3 to 5 fold increased risk 
of experiencing coronary artery disease or cerebrovascular disease compared 
with patients having normal uric acid levels51.  
URIC ACID AS A PROGNOSTIC MARKER IN HEART FAILURE 
                           Numerous parameters are capable of predicting prognosis in 
patients with chronic heart failure (CHF). Many of the modern parameters are 
only assessed by using research tests that are not widely available. There is a 
need for simple parameters that can be measured anywhere at low cost. Very 
few attempts have been made to develop scoring systems to predict prognosis 
in patients with CHF50,51, but these are not simple enough for general 
application. For prognostication in CHF, the following 3 main areas of relatively 
independent importance emerge: (1) a hemodynamic factor (for example, leR 
ventricular ejecSon fracSon [LVEF]); (2) the paSent’s funcSonal status (eg, peak 
oxygen consumpSon [VTO2]); and (3) a metabolic factor, including the 
neuroendocrine and immunologic processes.52  
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                            In patients with heart failure, high levels of serum uric acid are 
highly predictive of mortality and are useful in identifying the need for 
aggressive intervention. A graded relationship has been observed between 
serum uric acid and mortality in heart failure patients. These highlight the 
prognostic importance of serum uric acid along with other clinically established 
parameters. 
                            Patients with angiographically confirmed CAD with serum uric 
acid levels in the upper quartile were found to be five times more prone to 
mortality52. A 1-mg/dL increase in serum uric acid levels was associated with 
26% increase in mortality4. A study of Type II Diabetes mellitus showed that 
stroke incidence significantly increased by quartiles of serum uric acid levels 
and that high serum uric acid levels were significantly associated with risk of 
both fatal and nonfatal strokes. The increased risk was apparent even when 
other risk factors were taken into account. 
                            UA has also been identified as an effective predictor in several 
multiparametric HF models, such as the Seattle Heart Failure Model19 and, 
also, the Study of the Effects of Nebivolol Intervention on Outcomes and 
Rehospitalization in Seniors With Heart Failure (SENIORS) model. In both of 
these models, the predictive value of UA was independent of renal function, 
which was excluded from the Seattle Heart Failure model altogether. This 
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raises the important question of whether UA is a more useful prognostic factor 
than renal function and whether it should be included in conventional 
prognostic assessments of HF patients. 
                               SUA is a routinely measured variable in clinical laboratories, 
with repeatable results and nonsignificant short-term individual fluctuations 
without any age-specific or diurnal patterns20. Given these characteristics, SUA 
could feasibly be used as a helpful prognostic indicator in clinical practice.  
XANTHINE OXIDASE  INHIBITION AND HEART FAILURE  OUTCOMES 
                                 Recent clinical trials have suggested that XO inhibition may 
lead to improved mechanics and better clinical outcomes in patients with 
congestive HF (CHF). Numerous studies have reported that lowering UA levels 
improves endothelial reactivity49, myocardial function5, and ejection fraction47 
in patients with CHF and may lead to better clinical outcomes in a subgroup of 
HF patients with high SUA levels22.  
                                 Early clinical trials supported a role for UA in the loss of 
endothelium-dependent vasodilation in patients with CHF. After an initial 
study in 19 men with CHF, which reported that infusion of allopurinol 
improved endothelium-dependent vasodilation in hyperuricemic patients, a 
double-blind cross-study was performed in 14 men by Doehner, Anker et al 
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with hyperuricemia and CHF.42 When compared with placebo, treatment with 
allopurinol improved peak blood flow in the arms and legs while reducing 
levels of both UA and allantoin, a marker of oxygen-free radical generation. 
These findings were replicated in a second randomized, placebo-controlled, 
double-blind cross study in 11 patients with New York Heart Association 
(NYHA) class II or II CHF43 by Reyes et al. In this trial, daily treatment with 
allopurinol also led to improved endothelial-dependent vasodilation while 
reducing levels of plasma maldondialdehyde, another maker of oxidative 
stress. 
                               In both studies, the proposed mechanism was through an 
increase in the bioavailability of endothelium-derived NO, presumably by 
blocking the production of ROS produced by XO activity, as evidenced by the 
significant reduction in plasma biomarkers for oxidative stress. This hypothesis 
has been supported by several recent studies.  
                                 A recent preliminary, double-blind, placebo-controlled 
crossover study by Ogino and associates,48 UA lowering with the uricosuric 
agent benzbromarone in 14 patients with CHF and hyperuricemia did not 
improve hemodynamic impairment although SUA levels decreased 
significantly. These findings suggest that up-regulated XO activity rather than 
UA itself is involved in CHF pathophysiology and that the mechanism of 
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improvement with allopurinol may lie in its ability to reduce oxidative stress 
and not SUA levels. 
                   From a functional standpoint also, XO inhibition may lead to 
improvements in cardiac performance. An early study by Cappola and 
coworkers5 in patients with dilated cardiomyopathy, treatment with 
intracoronary allopurinol led to a significant decrease in myocardial oxygen 
consumption with no parallel decrease in stroke work, yielding a substantial 
improvement in myocardial efficiency. More recently, the La Plata Study47, a 
randomized, placebo-controlled, double-blind study in 60 patients with NYHA II 
or III CHF, demonstrated the ability of oxypurinol to improve left ventricular 
ejection fraction (LVEF) in patients with a baseline LVEF <40%. By potentially 
reversing the energetic inefficiency and improving the cardiac output of the 
failing circulation, pharmacologic XO inhibition may represent a novel 
therapeutic option for the treatment of HF. 
                    To the extent that XO inhibition may lead to improvement in clinical 
outcomes, the Efficacy and Safety Study of Oxypurinol Added to Standard 
Therapy in Patients With New York Heart Association Class III-IV Congestive 
Heart Failure (OPT-CHF) study randomized 405 patients with moderate to 
severe CHF due to systolic dysfunction to either oxypurinol or placebo.22 Using 
a composite end point of HF morbidity, mortality, and quality of life, oxypurinol 
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did not produce clinical improvements in unselected patients at 24 weeks. 
However, post hoc analysis suggested that patients with elevated levels of SUA 
(>9.5 mg/dL) might represent a responsive group, as there was a trend towards 
benefit in patients who received oxypurinol in this subgroup. Interestingly, the 
response to oxypurinol, as indicated by SUA reduction, correlated with the 
degree of clinical outcome in the high SUA group. Together, these findings 
suggest that SUA can serve as a valuable biomarker to target XO inhibition for 
select patients with HF, and does so in a manner that correlates with the 
degree of SUA reduction. 
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MATERIALS AND METHODS 
Study design                                      
             Case control study 
Setting 
              All patients were prospectively enrolled from the Cardiology and 
Internal medicine department of Government General Hospital, Chennai 3.  
Sample  
             100 patients with clinical evidence of heart failure were enrolled in this 
study. All patients had documented evidence of heart failure and were on 
heart failure treatment for at least one month. Informed consent was obtained 
from all patients. 40 age and sex matched controls were selected.  
Inclusion criteria  
Patients of both sex aged between 20 to 80 years 
Patients with Heart failure both with preserved and decreased EF. 
Patients with Heart failure of atleast 1 month duration 
 Exclusion criteria  
 Patients with pre existing gout and heart failure 
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 Patients on long standing diuretics and heart failure 
 Chronic kidney disease 
 Haematological malignancy 
 ATT –Pyrazinamide 
Procedure  
              A questionnaire prepared noted the duration, symptoms and 
treatment of heart failure. Questions were asked in relation to chest pain, 
dyspnoea, syncope, cough, smoking and medications. All previous clinical 
records of the patients were analyzed in detail. Based on the degree of effort 
needed to elicit symptoms, patients were assigned to NYHA class I to IV of 
heart failure. A detailed physical examination was conducted to assess 
patients’ volume status (rales, edema, jugular venous distension), weight, 
height, body mass index and orthostatic blood pressure changes. Complete 
blood count, blood glucose (fasting and 2 hour post prandial), fasting serum 
lipid profile, blood urea, serum creatinine and serum electrolytes were 
measured in all patients. Two-dimensional echocardiography was done in the 
cardiology department of Government General Hospital for all patients. Serum 
uric acid levels were measured on admission for all the 100 patients who met 
the inclusion criteria and compared with 40 age and sex matched controls. 
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Statistical significance was made out using the t test. Patients were followed 
up for a period of 30 days and prognosis was assessed by noting down 
symptomatic improvement or mortality. 
Instruments  
1. Electrocardiogram:  
All patients had 12 lead ECG, which was reviewed for evidence of atrial 
enlargement, ventricular hypertrophy, evidence of antecedent myocardial 
infarction and conduction blocks.  
2. Chest x ray:  
 Chest x ray posteroanterior view was done in all patients to note pulmonary 
congestion, pleural effusion and to estimate cardio thoracic ratio.  
3. Echocardiography:  
M-mode echocardiography was used to assess left ventricle dimensions. Left 
ventricle internal dimension in end systole (LVESD) and end diastole (LVEDD) 
were measured at the level of mitral valve leaflet tips in parasternal long axis 
view. Measurements were taken from the endocardium of the left surface of 
the interventricular septum to the endocardium of the left ventricle posterior 
wall. In adults the normal range of LVEDD is 3.5 to 5.6 centimeter. The normal 
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range of LVESD is 2 to 4 centimeter59. 2-D echo imaging in apical 4 chamber, 
parasternal long axis and parasternal short axis views were used to assess 
ventricular and valvular movement. Ejection fraction was estimated using 
Simpson’s method60. In this method multiple short axis views are taken along 
the LV long axis. Endocardial border is traced accurately and left ventricle 
cavity is divided into 20 slices of known thickness and diameter (D). Left 
ventricle end diastole and Left ventricle end systole volumes are estimated.  
Area of each slice=22/7 (D/2)2  
Volume of each slice = area X thickness.  
LV volume= volume of each slice X number of slices (20)  
 
EF  =        (Left ventricle end diastole volume -Left ventricle end systole                                 
                                                           volume) X 100 
                                      Left ventricle end diastole volume  
 
Laboratory methods  
              Fasting plasma glucose was measured using glucose oxidase and 
pyruvate oxidase methods from overnight fasting sample and results were 
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read by autoanalyser.2 hr postprandial glucose was measured 2 hrs after 
routine morning breakfast. 
              From patients height and weight, body mass index (BMI) was 
calculated using the formula weight in kilograms divided by square of height in 
meters. 
               Serum cholesterol (enzymatic oxidase-peroxidase method), Serum 
HDL (polyethylene glycol-CHOD-PAP method) Triglycerides (enzymatic 
calorimetric method) were measured using Erba XL 300 autoanalyser. Serum 
LDL was calculated using Friedewald’s formula61.  
1. Estimation of uric acid 
                It is the most oxidised member of the purine class of compounds. 
Further oxidation of uric acid in alkaline solution results in disruption of purine 
ring with removal of carbon 6 as carbon dioxide and formation of allantoin and 
other degradation compounds. Alloxan is the product of uric acid oxidation in 
acid solution. With addition of ammonia it forms ammonium purpurate, 
purplish red substance responsible for the well known murexide test for  uric 
acid, produced by heating uric acid and adding a few drops of ammonium 
hydroxide. Other Calorimetric methods for uric acid estimation are based on 
reducing properties of uric acid. 
41 
 
Method: Uricase method 
Principle: 
      Uricase converts uric acid to allantoin and hydrogen peroxide. The 
hydrogen peroxide  formed further reacts with phenolic compound and 4- 
Amino antipyrine by the catalytic action of peroxidase to form a red coloured 
quinoneimine dye complex. Intensity of the colour formed is directly 
proportional to the amount of uric acid present in the sample. 
            Uric acid + H2O     →              Allantoin + H2O2 
                H2O2 + 4- Amino antipyrine + Phenolic compound    →     Red 
quinoneimine dye +    H2O     
Normal values: 
Serum Uric Acid (males) = 3.0 to 7.0 mg/dl  
Serum Uric Acid (females) = 2.5 to 6.0 mg/dl  
2. Dyslipidemia76  
Any one of  
Serum total cholesterol >/= 200 mg/dl (Borderline High) 
Serum HDL </= 40 mg/dl(low)  
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Serum triglycerides >/= 200 mg/dl (High) 
 Serum LDL >/= 160 mg/dl(High) (ATP III guidelines)  
3. Diabetes mellitus77  
1. Plasma glucose of 126mg/dl or greater after overnight fasting  
2. Post prandial Plasma glucose of 200 mg/dl or greater  
3. Symptoms of DM with random glucose 200 mg/dl or greater  
4. HbA1C > 6.5% 
4. Systemic hypertension  
Based on JNC 8 classification systolic BP of 140 mm Hg and above and diastolic 
BP of 90 mm Hg and above was defined as systemic hypertension.  
5. Obesity  
Obesity is defined as body mass index more than 30 kg/m2. 
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Statistical analysis: 
Following statistical methods have been employed in the present study. 
• Independent samples ‘t’ test-Unpaired. 
• Independent samples ‘t’ test-Paired. 
• One-way Analysis of Variance (ANOVA). 
• Pearson correlation coefficient. 
• Relative risk. 
The study was approved by the ethics committee of the hospital  
                                                  
 
 
 
 
 
 
 
 
                                                     
 Table 1:  Age incidence 
In the study group of 100 patients with heart failure, 34% were in the age 
group of 40-50, 27% in the age group of 50
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     Table  2  : Age and sex incidence
 
In the study group of 100 patients with heart failure, 59% were males and 41% 
were females. Male:Female ratio was 1.43:1. In both males and females 
maximum incidence was seen in the age group of 40
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50 to 60 13 20
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Total 59 100
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 41 100 100 100 
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Table 3 :Type of heart failure  and no. of patients 
 
 
100 patients of heart failure were studied, among them, 59% were males and 
41% were females. Of the males 47% had CAD, 19% had COPD/cor pulmonale, 
10%  had RHD, 7% had DCM-unknown cause. Among the females 49% of CAD, 
20% had RHD, 10% had DCM unknown cause and 10% had peripartum 
cardiomyopathy. 
 Chart showing the distribution of various causes for heart
 
 
Chart showing the various causes of heart failure in both men and women:
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 Table 4: Major risk factors
   MAJOR RISK FACTORS IN PATIENTS WITH HEART FAILURE
RISK FACTORS 
NO. OF PATIENTS
MALE  
No.=59
NO 
SMOKING 41 
ALCOHOLISM 32 
HYPERTENSION 25 
DIABETES  21 
DYSLIPIDEMIA 18 
Out of the 100 patients studied, smoking was present in 41% of patients, 
hypertension in 38% of patients, 
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 Table 5:Major symptoms 
 
 
 
 
 
 
 
Among 100 patients 80% had dyspnea, 58% had pedal edema, 52% had 
orthopnea, 39% had oliguria and 33% had abdominal distension 
 
Chart showing the various symptomatology: 
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PATIENTS % 
DYSPNEA 80 80% 
PEDAL EDEMA 58 58% 
ORTHOPNEA 52 52% 
OLIGURIA 39 39% 
ABDOMEN DISTENSION 33 33% 
TOTAL 100 100 % 
 We have studied 100 patients
controls. Their comparative uric acid levels are given in the table below:
Table 6: Uric acid levels in patients and controls
PARAMETER 
AGE 
SR URIC ACID 
 
 
There was a statistically significant higher level of uric acid concentration in 
patients of heart failure as compared to controls (P<0.05).
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50 ± 19 47 ± 24 0.179 (NS)
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 Table 7: Patient profile and serum uric acid levels
PARAMETER 
SEX 
SR URIC ACID ON 
ADMISSION  
HYPERTENSION 
SR URIC ACID  
DIABETES MELLITUS 
SR URIC ACID  
 
There was no significant difference in serum uric acid levels as regards 
hypertension and diabetes mellitus in patients with heart failure, but there was 
a statistically significant difference in serum uric acid levels (p=0.0001) in male 
patients when compared to females.  
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 Table 8:Dyslipidemia and uric acid levels
 
Dyslipidemia Present(No.=29)
Mean SUA 7.16 
 
Dyslipidemia was present in 71 % of the individuals and it was absent in 29% of 
the individuals. The mean serum uric acid  was 
dyslipidemia and 6.01 mg/dl in those without dyslipidemia. The mean serum 
uric acid between the two groups was compared by the unpaired t test and it 
was found that the p value was > 0.9999 and it was not significant.
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 dyslipidemia: 
 
 Table 9.Comparison of uric acid levels with causes of heart failure
CAUSE OF HEART 
FAILURE 
 
CAD(n=48)
Mean serum uric 
acid in mg/dl 
6.13 
 
The mean serum uric acid levels were compared among the three common 
causes of heart failure encountered in the study. It was found that the p value 
was 0.05 and it was not that significant using the ANOVA test.
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To find out correlation between duration of heart failure and serum uric acid 
Pearson’s coefficient was used and the results were as follows: 
                          Correlation coefficient (r) = -0.05287 
                          95% confidence interval: -0.2468 to 0.1451 
                          Coefficient of determination (r squared) = 0.002795 
                          The two-tailed P value was 0.6014, considered not significant. 
Hence it was inferred that there was no correlation between duration of heart 
failure and levels of serum uric acid. 
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Table 10: Uric acid in correlation with NYHA Class of heart failure 
 
NYHA Class of 
heart failure 
 
Class II(N=19) Class III(N=76) Class IV(N=5) 
Mean Uric acid 4.59 6.59 9.38 
Standarddeviation 1.8914 1.832 1.892 
 
Comparison      Mean difference q P value   
Class II vs Class III -2.010    4.486   P<0.01 
Class II vs Class IV -4.800    7.232 P<0.001 
Class III vs Class IV -2.790    4.124   P<0.05 
According to the Tukey-Kramer Multiple Comparisons Test if the value of q is 
greater than 3.455 then the P value is less than 0.05. 
Among the 100 patients 19 were in  class II HF, 76 patients were in class III HF 
and 5 were in class IV HF. The serum uric acid among the three groups was 
compared using the ANOVA test and was found to be statistically significant. 
The P value was < 0.0001, considered extremely significant. Variation among 
column means was significantly greater than expected by chance. Patients in 
class IV HF had higher uric acid levels than those on class III and class II HF. 
 Chart showing the serum Uric acid levels in correlation with NYHA Class of 
heart failure: 
To find out correlation between Ejection fraction and serum uric acid Pearson’s 
coefficient was used and the results were as follows:
                     Correlation coefficient (r) = 
                     95% confidence interval: 
                     Coefficient of determination (r squared) = 0.03023
                     The two-tailed P value was 0.0836, considered not quite significant.
Hence it was inferred that there was  no correlation between Ejection fraction 
and serum uric acid. 
 
 
4.59
0
1
2
3
4
5
6
7
8
9
10
Class II(N=19)
SERUM URIC ACID LEVELS IN VARIOUS STAGES OF HF
 
-0.1739 
-0.3581 to 0.02341 
 
6.59
9.38
Class III(N=76) Class IV(N=5)
57 
 
 
58 
 
Table 11.Uric acid levels before and after treatment of HF 
PARAMETER 
UA BEFORE 
TREATMENT 
UA AFTER 
TREATMENT 
P VALUE 
 
No.= 100 No.  =  100 
MEAN SR URIC ACID 6.35 6.04 0.1756(NS) 
The mean serum uric acid levels of the patients were compared before and 
after treatment of HF and it was found that p >0.05, not significant. 
Out of the 100 patients, 20 patients were lost follow up and in the remaining 
80 patients 13 Patients expired.0ut of the 13 patients 11 had higher uric acid 
levels. 5 of them were in class IV heart failure and 6 were in stage III heart 
failure with mean uric acid level of 8.9 mg/dl. This graph below depicts the uric 
acid levels in those who expired. 
 
It was found that mean uric acid level was 8.9 mg/dl in those who expired. 
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The mean serum uric acid level between those patients who are alive were 
compared with those who expired and it was found 
<0.05. 
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DISCUSSION 
 
                    Elevated SUA levels have been associated with an increased risk for 
cardiovascular disease.29 Serum uric acid level is an index of oxidative stress in 
the human body30.  Serum uric acid is known to contribute to endothelial 
dysfunction by impairing nitric oxide production.31 Serum uric acid has also 
been shown to be inversely correlated with the measures of functional 
capacity and maximal oxygen intake. Among patients with chronic heart 
failure, serum uric acid concentrations are associated with greater activity of 
superoxide dismutase and endothelium-dependent vasodilatation.32  
                    Another potential pathophysiological link between hyperuricemia 
and heart failure might be through inflammation. Asymptomatic 
hyperuricemia is a proinflammatory state associated with higher levels of 
serum markers of inflammation, such as C-reactive protein, interleukin-6, and 
neutrophil count.31,33,34 Among patients with heart failure, hyperuricemia is 
associated with higher levels of markers of endothelial activation, such as the 
soluble intercellular adhesion molecule-1, and inflammatory markers such as 
interleukin-6, tumor necrosis factor-α, and its receptors. Similar observations 
have been made in some population-based studies35 and hospital-based 
studies. The risk of heart failure was proportionate to the degree of elevation 
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of serum uric acid among patients with gout.36 Locally, even when there is no 
active arthritis, the synovial fluid of patients with gout shows low-grade 
inflammatory activity.37  
                  Increased levels of serum uric acid among normal individuals predict 
hypertension,27,38 renal dysfunction,25 and coronary artery disease22 and 
portend reduced life expectancy.39 Lowering of serum uric acid with allopurinol 
can reduce blood pressure among hypertensives.40,41 This raises the possibility 
of the hyperuricemia-heart failure link being mediated by hypertension, a 
hypothesis that cannot be directly tested in observational studies. 
Nevertheless, some studies have shown that hyperuricemia is an independent 
risk factor for heart failure among those who already have hypertension.  
                  We have studied 100 patients with heart failure and 40 age and sex 
matched controls. These patients were admitted to our hospital during June to 
November 2011. Their comparative uric acid levels are given in the table 
above.  
                   The mean age group of patients with heart failure found in our study 
was 50 years with the minimum age of 27 years and the maximum age of 69 
years. Out of the 100 patients of heart failure 59% were males and 41% were 
females. The mean age in men was found to be 50 years and in women was 
found to be 49.41 years. 
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                 40 controls were selected from patients admitted for other causes 
like fever and from healthy volunteers. Controls did not have any co-morbid 
illness. The mean age among controls was 47 years. To find out if the controls’ 
age differed from that of the patients the unpaired t test was used and it was 
found that the P value was 0.1714 considered not significant. The male:female 
ratio among controls and patients were similar the results being 1.5:1 and 
1.45:1 respectively. In both males and females maximum incidence was seen in 
the age group of 40-50 years 
                 The mean serum uric acid found in our study was 6.35 mg/dl as 
compared to the control value of 3.61 mg/dl. The mean uric acid in men was 
7.4 mg/dl   and in women it was 4.83 mg/dl. There was no correlation between 
age and serum uric acid made in our study. 
               Of the males 47% had CAD, 19% had COPD/ cor pulmonale, 10% had 
RHD, 7% had DCM-unknown cause. Among the females 49% of CAD, 20% had 
RHD, 10% had DCM unknown cause and 10% had peripartum cardiomyopathy. 
The most common cause for HF was found to be CAD in our study. Our study 
did not find any correlation between EF and serum uric acid levels and also 
between duration of heart failure and uric acid levels. 
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                  Among 100 patients 80% had dyspnea, 58% had pedal edema, 52% 
had orthopnea, 39% had oliguria and 33% had abdominal distension. So 
according to our study dyspnea was the most common symptom which 
necessitated hospitalisation. 
                    There was no significant difference in serum uric acid levels as 
regards hypertension and diabetes mellitus in patients with heart failure, but 
there was a statistically significant difference in serum uric acid levels 
(p=0.0001) in male patients when compared to females. This is in concordance 
with the study by Tuomilheto et al78 in which there was no significant 
association between serum uric acid level and diabetic levels. 
                   Dyslipidemia was present in 71 % of the individuals and it was 
absent in 29% of the individuals. There was no significant difference in serum 
uric acid levels as regards to the presence and absence of dyslipidemia.   
                    The mean serum uric acid levels were compared among the three 
common causes of heart failure encountered in the study that is CAD, RHD and 
COPD/cor pulmonale . It was found that the p value was > 0.9999 and it was 
not significant using the ANOVA test.  
                      Among the 100 patients 19 were in class II HF, 76 patients were in 
class III HF and 5 were in class IV HF. The serum uric acid among the three 
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groups was compared using ANOVA test and was found to be statistically 
significant p<0.05. Patients in class IV HF had higher uric acid levels than those 
on class III and class II HF. Hence we observed that as the class of HF worsened 
there was an increase in uric acid as well. 
                The mean serum uric acid levels of the patients were compared 
before and after treatment of HF and it was found that p >0.05, not significant. 
Hence we inferred that probably uric acid is not just a marker but it has a 
causative role as well. However due to the presence of co-morbid illnesses 
which also influence the uric acid levels, this could not be hypothesised. 
                The observations that we have made suggests a role for primary 
prevention of heart failure. But the literature is conflicting on whether a 
reduction in serum uric acid will result in measurable clinical benefit among 
those with established heart failure.42,43 Some studies have even shown that 
that increased serum uric acid caused by diuretic use might have a beneficial 
role in itself.43 On the other hand, the Losartan Intervention For Endpoint 
reduction in hypertension (LIFE) study has found that the uricosuric property of 
Losartan, has a beneficial effect among patients with hypertension and left 
ventricular remodelling and hypertrophy.44 The mechanisms by which uric acid 
reduction treatments is beneficial is not clear. Specifically, it is unclear whether 
the observed benefit from the use of xanthine oxidase inhibitors is mediated 
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through reduction in serum uric acid levels or some other mechanism. 
Inhibition of xanthine oxidase enzyme by allopurinol has beneficial effects in 
terms of improved peripheral vasodilator capacity, systemic blood flow, and 
clinical outcomes.45,46 Randomized controlled studies are also unclear about 
the potential benefits of allopurinol or its metabolite oxypurinol on heart 
failure. The La Plata study showed an improvement in left ventricular ejection 
fraction with the use of allopurinol47  but the Oxypurinol Therapy for 
Congestive Heart Failure (OPT-CHF) study did not show an overall benefit.48  
                    At the end of 30 days’ follow up, 13 Patients expired in our study. 2 
of them had normal uric acid levels. Out of the 11 patients who had higher uric 
acid levels, 5 were in class IV heart failure and 6 were in class III heart failure. 
Their mean uric acid was found to be 8.9 mg/dl with a minimum of 7.1 mg/dl 
and a maximum of 12 mg/dl. The relative risk of all cause mortality in those 
with uric acid > 7.0 mg/dl was found to be 5.72 as compared to 0.1745 for 
those with uric acid < 7.0mg/dl . The significance of difference in serum uric 
acid between those who were alive and those who expired was made out using 
unpaired t test and was found to be extremely significant p<0.001. This is in 
concordance with other studies as shown in the table below: 
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SOURCE NO. EF % FOLLOW 
UP mth 
SUA in 
mg/dl 
DEATH % 
Pascual-
Figal et al9 
(2007) 
212 31±8 20.4 <5.8 
 5.8–7.2 
7.2–9.1 
 
3. 4 
17 
60 
Jankowska 
et al15 
(2007) 
119 32±8 48.3 <6.5 
>6.5 
11 
 29 
Sakai et 
al16 (2006) 
148 35±1 42 <6 
>6 
8 
26 
Anker et 
al10 (2003) 
294 26±15 51 <6.7 
6.7-10 
10.1-13.4 
>13.4 
27 
40 
82 
100 
Alimonda 
et al11 
(2009) 
560 NR 12 <7.7 
>7.7 
21 
38 
Niizeki et 
al8 (2006) 
123 40±18 38 <5 
5.1-6.4 
6.5-8.6 
>8.6 
10 
22 
30 
60 
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                     In summary, our study found that hyperuricemia is associated with 
greater incidence of heart failure and hyperuricemia is a predictor of all cause 
mortality in patients with heart failure. Future studies using various urate 
reduction treatment strategies would be needed to determine whether 
primary prevention of heart failure is possible. As the prevalence of heart 
failure is increasing , even a small clinical benefit derived from such studies can 
be of enormous benefit to the community.  
                      Our study had certain limitations. Our sample size was only 100. 
Moreover, patients were followed for only 30 days and  increasing the duration 
of follow up to at least 6 months or one year would have provided a better 
assessment of differences in mortality between the two groups.  
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                                                         CONCLUSION 
 Serum uric acid levels are higher in patients of heart failure as compared 
to normal age and sex matched healthy persons. 
 
 Patients in higher NYHA Class of heart failure have higher serum uric acid 
levels, thus serum uric acid levels correlated with NYHA Class of heart 
failure. 
 
 Uric acid is not only a bystander marker but probably also a causative 
marker of mortality in patients who have heart failure. 
 
 Combination of NYHA Class of heart failure and serum uric acid level is a 
good predictor of mortality of heart failure. 
 
 Any drug interventions, such as therapy to decrease serum uric acid in 
addition to other drugs used in heart failure, may have a favourable 
outcome in patients who have heart failure. Further prospective studies 
are needed to clarify this aspect. 
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                                                  PROFORMA 
 
Name:      Age:  Sex: 
Address:      Occupation: 
 
Duration and details of cardiac illness: 
 
Symptoms: 
 
    Dyspnea     Nocturia  
    Orthopnea     Puffiness of Face  
    PND     Chest pain  
    Oliguria     Anorexia  
    Abdominal distension       
    Swelling of legs     Easy fatiguability  
     
Past history:     Drug history: 
    DM     
    Hypertension        
    Tuberculosis 
 
Personal history: 
    Smoking     Alcoholism     
     
 
   
General examination: 
Anthropometry: 
Ht:             Wt:                 
Hydration Status:                JVP: 
Pulse:                                     Blood pressure: 
 
Systemic examination: 
CVS: RS: ABDOMEN:                  CNS: 
 
NYHA class of heart failure: 
 
Investigations: 
Hb:             TC:  DC:  P-     L-       E-       M- Plt:       ESR: 
Blood Glucose Fasting : 
Blood Urea : 
Serum Creatinine : 
Serum Electrolytes : Na+   K+  
Total Cholesterol : HDL : 
Triglycerides : LDL : 
Liver function test         :  
Bilirubin Total                 : 
               Direct                : 
SGOT                                : 
SGPT                                 : 
Total Protein                   : 
         Albumin                  : 
         Globulin : 
Sr. Alkaline Phosphatase : 
 
Urine examination: 
 
ECG: 
 
X-ray chest pa view : 
 
Echocardiogram :  
 
Serum uric acid on  :    Treatment given: 
admission 
 
Serum uric acid : 
after treatment 
 
MASTER CHART FOR PATIENTS 
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1 GANESAN 55 M P P A P A P A A A A A A A A 12 P P P P 45 III P 8.6 8.3 A 
2 RAJENDIRAN 52 M A A A A A P A A A A A A A A 9 A P P A 48 II A 4.2 3.9 A 
3 LAKSHMI 60 F P P P P P P A A A A A A A A 18 P P A A 40 III P 4.5 4.1 P 
4 ANBU 50 M P P P P P A A P A A A A A A 6 A A P P 55 II A 9.9 9.9 P 
5 KUPPUSAMY 65 M P P A P A A A A P A A A A A 24 A A A P 50 III P 8.2 7.4 A 
6 KANNAGI 55 F A A A A A P A A A A A A A A 24 A A A A 48 II A 1.8 1.6 A 
7 JOTHI 50 F A A A A A P A A A A A A A A 12 A A A A 48 II A 2.4 2.3 A 
8 LALITHA 62 F A A A A A A A A P A A A A A 8 A A A A 49 II A 3.2 2.9 A 
9 ANNAMALAI 55 M P A A P A P A A A A A A A A 6 A P A P 42 III A 7.4 7.1 A 
10 DHANAPAL 59 M P A A P A P A A A A A A A A 15 A P P P 45 III A 7.3 6.9 A 
11 MURUGAN 46 M P P P P P A A A A A P A A A 15 A A A A 35 IV P 11 12 P 
12 KATHIRVEL 45 M P A A A A P A A A A A A A A 14 P P P P 50 III A 4.9 4.6 P 
13 VIMALA 40 F P P P P P A A A A A P A A A 12 A A A A 34 III A 7.2 6.8 A 
14 ARUMUGAM 42 M P P P P P A A A A A A A P A 8 A A P P 40 III A 6.9 6.6 A 
15 KANCHANA 55 F P A A P A P A A A A A A A A 6 P P A A 48 III P 5.8 5.3 A 
16 PERIYASAMY 32 M P A A A A P A A A A A A A A 8 A P A A 45 III A 7.9 6.6 A 
17 SRINIVASAN 40 M A A A A A P A A A A A A A A 12 A A P A 45 III A 6 5.5 A 
18 RANI 45 F P P P P P A P A A A A A A A 24 A A A A 48 III A 5.4 5.1 A 
19 LEELAVATHY 28 F P P A P A A A A A A A A A P 1 A A A A 45 III A 4.8 4.2 A 
20 SHANMUGAM 62 M P P P P P A A P A A A A A A 9 A A P P 56 IV P 7.4 7.2 P 
21 VIJAYAKUMAR 45 M P P P P P A A A A P A A A A 18 A A P P 48 III P 6.9 7.1 P 
22 BHARANIVELAN 40 M P A A P A P A A A A A A A A 24 P A A A 48 III P 10 9.9 P 
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23 LOGAMMAL 65 F P A A P A P A A A A A A A A 15 P P A A 51 III P 6.2 6.1 A 
24 DEVAKI 50 F A A A A A A P A A A A A A A 18 A A A A 60 II A 3.4 2.6 A 
25 PARAMASIVAM 62 M P A A A P A A P A A A A A A 13 P A P A 58 III A 7.4 7.3 A 
26 KRISHNAMMAL 58 F P A A P A P A A A A A A A A 24 A P A A 48 III A 5.4 5.1 A 
27 VELAYUDHAM 60 M P P P A P A A P A A A A A A 24 A A P P 55 III A 5.9 5.4 A 
28 SULOCHANA 59 F P P A A P P A A A A A A A A 15 P A A A 45 III A 6.5 6.4 A 
29 MANNANGATTI 62 M A A A A A P A A A A A A A A 14 P P P P 48 II A 4.9 4.7 A 
30 SUSEELA 65 F A A A A A P A A A A A A A A 13 P P A A 40 II A 1.2 1.2 A 
31 JEYASEELAN 35 M P P P P P A A A A A A P A A 8 A A A P 35 III A 8.2 8.1 P 
32 PADMANABAN 60 M P A A A A P A A A A A A A A 12 P P P P 48 II A 7.4 7.1 A 
33 RENUKA 28 F P A A P A A A A A A A A A P 1 A A A A 49 III A 3.4 3.2 A 
34 SIVAGAMI 50 F P P A P P P A A A A A A A A 18 P P A A 35 III P 6.9 6.7 A 
35 LATHA 51 F P P P P P A P A A A A A A A 36 A A A A 52 III A 4.9 4.6 A 
36 NAGOORAN 50 M P A A P A A P A A A A A A A 18 A A P A 62 III A 4.2 4 A 
37 DAVID 60 M P P P P P A A P A A A A A A 24 P A P A 58 III P 8.2 8.1 P 
38 KUYILAMMAL 65 F P P A P A P A A A A A A A A 18 P A A A 37 III P 3.2 3.1 A 
39 EGAMBARAM 58 M P P P P P P A A A A A A A A 16 A A P P 26 III A 8.1 7.9 A 
40 RAVAKANNU 62 M P P A P A A P A A A A A A A 18 A A P A 50 III A 6.9 6.4 A 
41 KARPAGAMMAL 55 F P P A P A P A A A A A A A A 13 A A A A 42 III A 6.7 6.1 A 
42 LOGHU 42 M P P P P P A A A A A A P A A 5 A A P P 28 IV P 11.3 11.1 P 
43 VIJAYA 58 F P A A A A P A A A A A A A A 18 P A A A 35 III P 5.6 5.1 A 
44 MAGENDRAN 50 M P A A P A P A A A A A A A A 24 P P P P 29 III A 8.4 8.5 P 
MASTER CHART FOR PATIENTS 
 
NO. NAME AGE SEX 
SYMPTOMS CAUSE OF HF                       
D
Y
S
P
N
E
A
 
O
R
T
H
O
P
N
E
A
 
A
B
D
O
M
E
N
 
D
I
S
T
E
N
S
I
O
N
 
P
E
D
A
L
 
E
D
E
M
A
 
O
L
I
G
U
R
I
A
 
C
A
D
 
R
H
D
 
C
O
P
D
/
C
O
R
 
P
U
L
M
O
N
A
L
E
 
C
A
L
C
I
F
I
C
 
A
S
/
A
R
 
E
I
S
E
N
M
E
N
G
E
R
 
S
Y
N
.
 
D
C
M
-
C
A
U
S
E
 
U
N
K
N
O
W
N
 
A
L
C
O
H
O
L
I
C
 
C
.
M
Y
O
P
A
T
H
Y
 
R
V
D
 
P
E
R
I
P
A
R
T
U
M
 
D
U
R
A
T
I
O
N
 
I
N
 
M
O
N
T
H
S
 
D
M
 
S
H
T
 
S
M
O
K
I
N
G
 
A
L
C
O
H
O
L
 
E
F
 
N
Y
H
A
 
C
L
A
S
S
 
D
Y
S
L
I
P
I
D
E
M
I
A
 
U
.
A
 
m
g
/
d
l
 
D
A
Y
1
 
U
.
A
 
A
F
T
E
R
 
T
R
E
A
T
M
E
N
T
 
M
O
R
T
A
L
I
T
Y
 
45 RAMACHANDRAN 69 M P P P P P A A P A A A A A A 18 A A P P 58 III A 6.7 6.2 A 
46 RAJESHWARI 42 F P P A A A A A A A P A A A A 3 A A A A 58 III A 4.5 4.2 A 
47 PONNURANGAN 48 M A A A A A A P A A A A A A A 12 P P P P 45 II A 4.1 3.9 A 
48 ARUMUGAM  49 M P P A A A A P A A A A A A A 13 A A A A 48 III A 6.4 6.1 A 
49 PARAMESHWARI 49 F P P A A P A P A A A A A A A 18 A A A A 52 III P 1.8 1.6 A 
50 ARJUNAN 42 M P P P P A A A A A A A A P A 3 A A A A 42 III P 8.7 8.2 A 
51 SHANTHI 55 F P P A A A P A A A A A A A A 6 P P A A 48 III A 5.8 5.4 A 
52 BUVANA 62 F P P A A A P A A A A A A A A 12 P P A A 35 III A 4.9 4.2 A 
53 SEKAR 68 M P P A P A A P A A A A A A A 24 A A P P 58 III P 7.9 7.3 A 
54 MOHAN 35 M P P P P P A A P A A A A A A 8 A A P A 42 III A 7.9 7.6 A 
55 VETRIVEL 45 M P P P P P A A A A A P A A A 4 A A P A 35 III A 8.4 8.3 A 
56 SANGEETHA 32 F P A P A A A P A A A A A A A 24 A A A A 48 III A 5.6 5.4 A 
57 SUNDARAM 49 M P A A A A A P A A A A A A A 12 P P P P 42 III A 3.4 4.2 A 
58 MOHD. BEGUM 52 F P A A A P A A P A A A A A A 24 A A A A 48 III A 3.8 3.9 A 
59 MOHD. IQBAL 49 M A A A A A P A A A A A A A A 24 P P P A 49 II A 7.9 6.1 A 
60 KANNIYAPPAN 52 M A A A A A P A A A A A A A A 12 P P P P 39 II A 8.2 7.9 A 
61 SENTHIL KUMAR 53 M P P A P A P A A A A A A A A 12 P P P P 44 III A 8.2 7.4 A 
62 PALANIAPPAN 50 M A A A A A P A A A A A A A A 9 A P P A 47 II P 5.6 5.3 A 
63 BANUMATHY 61 F P P P P P P A A A A A A A A 18 P P A A 39 III A 6.4 6.3 A 
64 KONDAIAH 49 M P P P P P A A P A A A A A A 6 A A P P 54 III A 8.4 7.9 A 
65 KASINATHAN 64 M P P A P A A A A P A A A A A 24 A A A A 49 III A 8.2 7.2 A 
66 MANJULA 54 F A A A A A P A A A A A A A A 24 A A A A 47 II P 5.6 5.4 A 
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67 DEVI 49 F A P A P A A P A A A A A A A 12 A A A A 57 II P 4.8 4.7 A 
68 PARIMALA 61 F A A A A A A A A P A A A A A 8 A P A A 48 II P 4.7 4.6 A 
69 DEVANATHAN 54 M P A A P A P A A A A A A A A 6 A P P P 41 III A 9.8 9.6 A 
70 BAALAIAH 58 M P A A P A P A A A A A A A A 24 A A A A 34 III A 6.4 6.1 A 
71 MURUGESAN 45 M P P P P P A A A A A P A A A 15 P P P P 49 IV A 9.8 9.6 P 
72 SAKTHIVEL 44 M P A A A A P A A A A A A A A 14 A A A A 33 III A 4.9 4.6 A 
73 VANAJAMMAL 39 F P P P P P A A A A A P A A A 12 A A A A 39 III A 6.4 6.1 A 
74 PANDIYAN 42 M P P P P P A A A A A A A P A 8 P P A A 47 III P 8.8 8.2 A 
75 KALAIYARASI 54 F P A A P A P A A A A A A A A 6 A P A A 44 III P 5.8 5.6 A 
76 SAMIKANNU 31 M P A A A A P A A A A A A A A 24 A A P A 44 III A 8.9 8.6 A 
77 VASAN 39 M A A A A A P A A A A A A A A 15 A A A A 47 III A 6 5.5 A 
78 RATHI 44 F P P P P P A P A A A A A A A 14 A A A A 44 III A 6.1 5.9 A 
79 SORNA 27 F P P A P A A A A A A A A A P 12 A A A A 55 III A 4.8 4.2 A 
80 GOVINDAN 61 M P P P P P A A P A A A A A A 8 A A P P 47 III P 8.9 8.6 A 
81 JEYENDRAN 45 M P P P P P A A A A A P A A A 14 A A A A 35 IV P 7.4 7.1 P 
82 BALAN 44 M P A A A A P A A A A A A A A 12 P P P P 49 III A 4.8 4.3 A 
83 LOGESHWARI 39 F P P P P P A A A A A P A A A 11 A A A A 33 III A 4.2 3.9 A 
84 DEVAN 41 M P P P P P A A A A A A A P A 9 A A P P 38 III A 9.1 8.7 A 
85 CHINNASAMY 41 M P P P P P P A A A A A A A A 4 P A P A 34 III A 7.4 7.3 A 
86 KRISHNAVENI 56 F P A A P A P A A A A A A A A 18 P P A A 42 III A 4.3 4.3 A 
87 VIJAYENDRAN 31 M P A A A A P A A A A A A A A 7 A P A A 44 III P 7.9 7.4 A 
88 SRIDEVI 44 F P A A A A P A A A A A A A A 13 P P A A 49 III A 4.8 4.6 A 
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89 MADURAI 61 M A A A A A P A A A A A A A A 13 P P P P 47 II A 4.9 4.6 A 
90 SANGAVI 27 F P P A P A A A A A A A A A P 1 A A A A 44 III A 3.2 2.8 A 
91 KUMAR 44 M P P P P P A A A A A A A P A 7 A A P P 47 III P 9.8 9.2 A 
92 PALANIVEL 39 M P A A P A P A A A A A A A A 24 P A A A 47 III P 8.9 8.2 A 
93 KANNAGI 49 F A A A A A A P A A A A A A A 17 A A A A 54 II A 3.1 2.9 A 
94 MUNUSAMY 61 M P A A A P A A P A A A A A A 23 A P A A 53 III A 8.4 8.1 A 
95 KRISHNAN 62 M P A A A P A A P A A A A A A 18 A P A A 52 III P 7.4 7.1 A 
96 VENI 57 F P P A A P P A A A A A A A A 14 P A A A 44 III A 6.2 5.9 A 
97 PALANI 59 M A A A A A P A A A A A A A A 13 P P P P 47 II A 4.9 4.6 A 
98 PRIYA 34 F P P P P P A A A A A P A A A 11 A A A A 33 III A 5.6 5.3 A 
99 KAMALAKANNAN 61 M A A A A A P A A A A A A A A 12 P P P P 48 II A 4.9 4.8 A 
100 HEMALATHA 40 F P P P P P A A A A P A A A A 10 A A A A 62 III A 7.4 7.3 A 
 
KEY TO MASTER CHART:CAD=Coronary artery disease;RHD=Rheumatic heart disease;COPD=Chronic obstructive pulmonary 
disease;SYN=Syndrome;AS/AR=Aortic stenosis/aortic regurgitation;DCM=Dilated cardiomyopathy;RVD=Retroviral disease 
DM=Dibetes mellitus;SHT=Systemic hypertension;EF=Ejection fraction;NYHA=Newyork heart association;U.A=Uric acid; 
A=Absent;P=Present 
                             
 
 
MASTER CHART FOR CONTROLS 
 
 
 NAME   AGE SEX 
S.U.A 
(mg/dl) 
1 RENUGA DEVI 27 F 2.9 
2 RAJESWARI 41 F 3.2 
3 KUNJAMMAL 68 F 4.2 
4 RAJENDRAN 64 M 3.4 
5 THAVAMANI 45 F 3.7 
6 REJINA 33 F 3.9 
7 SANTHA 60 F 3.4 
8 LATHA 25 F 3.3 
9 PRAKASH 33 M 3.7 
10 RAMESH 32 M 3.9 
11 JACOB 41 M 3.7 
12 NAGARAJ 50 M 3 
13 NARAYANASAMY 68 M 3.2 
14 VEERAPPAN 62 M 4.5 
15 KUSALAVAN 44 M 3.7 
16 GOVINDARAJAN 58 M 2.8 
17 MURTHY 67 M 3.3 
18 VENKATESH 33 M 3.8 
19 PRABHU 30 M 2.9 
20 PETHARAJ 48 M 3.1 
21 SANKARI 28 F 3 
22 PRIYA 42 F 3 
23 DEVI 26 F 3.2 
24 KALA 65 F 3.6 
25 RAMA 46 F 3.8 
26 UMA 34 F 4 
27 MARIAMMAL 66 F 4 
28 GEETHA 65 F 4.2 
29 BOMMI 34 F 3.8 
30 SELVAM 33 M 4 
31 SHYAM 42 M 3.8 
32 VIGNESH 66 M 3.2 
33 KISHORE 52 M 3 
34 NIRMAL 44 M 3 
35 MANOHAR 58 M 4.6 
36 SUBHASH 63 M 4.5 
37 GOPU 54 M 4.1 
38 SELVAM 67 M 4 
39 VISWA 38 M 3.9 
40 RAMU 28 M 4.1 
KEY:U.A=Uric acid 
    

